Abstract:Pandemic new severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus has increased throughout the world. There is no effective treatment against this virus until now. Since its appearance in Wuhan, China in December 2019, SARS-CoV-2 becomes the largest challenge the world is opposite today, including the discovery of an antiviral drug for this virus. Several viral proteins have been prioritized as SARS-CoV-2 antiviral drug targets, among them the papain-like protease (PLpro) and the main protease (Mpro). Inhibition of these proteases would target viral replication, viral maturation and suppression of host innate immune responses. Potential candidates have been identified to show inhibitory effects against Mpro, both in biochemical assays and viral replication in cells. There are different molecules such as lopinavir and favipiravir considerably inhibit the activity of Mpro in vitro. Different studies have shown that structurally improved favipiravir and other similar compounds can inhibit SARS-CoV-2 main protease. In this work, we study the interactions between favipiravir with Mg 12 O 12 and Zn 12 O 12 nanoclusters by density functional theory (DFT) and quantum mechanics atoms in molecules (QMAIM) methods to summarize the ability to load favipiravir onto Mg 12 O 12 and Zn 12 O 12 nanoclusters. Favipiravir-Mg 12 O 12 and favipiravir-Zn 12 O 12 lowest structures complexes were chosen to dock inside the SARS-CoV-2 main protease by molecular docking study. The molecular docking analysis revealed that the binding affinity of Mg 12 O 12 and Zn 12 O 12 nanoclusters inside the Mpro receptor is larger than that of favipiravir. Also, the loading of favipiravir on the surface of Mg 12 O 12 and Zn 12 O 12 nanoclusters increased the binding affinity against the Mpro receptor. Subsequently, 100 ns molecular dynamics simulation of the favipiravir-Mg 12 O 12 , and favipiravir-Zn 12 O 12 docked inside the Mpro complexes established that favipiravir-Mg 12 O 12 , forms the most stable complex with the Mpro. Further molecular mechanics Poisson Boltzmann surface area (MMPBSA) analyses using the MD trajectories also demonstrated the higher binding affinity of favipiravir-Mg 12 O 12 inside the Mpro. In summary, this study demonstrates a new way to characterize leads for novel anti-viral drugs against SARS-CoV-2, by improving the drug ability of favipiravir via loading it on Mg 12 O 12 and Zn 12 O 12 nanoclusters. Communicated by Ramaswamy H. Sarma

Disulfiram inhibits coronaviral main protease by conjugating to its substrate entry site

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

Discovery of a Highly Promising Disulfide Derivative Scaffold as Inhibitor of SARS-CoV-2 main protease

Structural basis for the inhibition of coronaviral main proteases by PF-00835231

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors

Structural Basis for Coronaviral Main Proteases Inhibition by the 3clpro Inhibitor GC376.

Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor

Structural Basis for coronaviral main proteases Inhibition by a 3CL Protease Inhibitor- GC376

Acriflavine and proflavine hemisulfate as potential antivirals by targeting Mpro

The S1′–S3′ Pocket of the SARS‐CoV‐2 Main Protease is Critical for Substrate Selectivity and Can Be Targeted with Covalent Inhibitors

Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg12O12 and Zn12O12 nanoclusters: an in silico strategy for COVID-19 treatment

Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

A computational evaluation of targeted oxidation strategy (TOS) for potential inhibition of SARS-CoV-2 by disulfiram and analogues

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors

In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Investigating the Inhibition of Diindolylmethane Derivatives on SARS‐CoV‐2 Main Protease

Inhibition of Subunit Exchange and N-Finger Rearrangement in SARS-CoV-2 Main Protease by Peptidomimetic Inhibitors

Evaluation of inhibition effect and interaction mechanism of antiviral drugs on main protease of novel coronavirus: molecular docking and molecular dynamics studies